JP2006514942A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006514942A5 JP2006514942A5 JP2004558286A JP2004558286A JP2006514942A5 JP 2006514942 A5 JP2006514942 A5 JP 2006514942A5 JP 2004558286 A JP2004558286 A JP 2004558286A JP 2004558286 A JP2004558286 A JP 2004558286A JP 2006514942 A5 JP2006514942 A5 JP 2006514942A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- chloro
- methyl
- compound
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 27
- 150000003839 salts Chemical class 0.000 claims 24
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 17
- 239000001257 hydrogen Substances 0.000 claims 17
- 239000000651 prodrug Substances 0.000 claims 14
- 229940002612 prodrug Drugs 0.000 claims 14
- 125000001424 substituent group Chemical group 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 229920006395 saturated elastomer Polymers 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 5
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 5
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 3
- 229940122820 Cannabinoid receptor antagonist Drugs 0.000 claims 3
- 239000003536 cannabinoid receptor antagonist Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- KIJMGJWYLBFNAV-UHFFFAOYSA-N 1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]-2-(1-oxa-8-azaspiro[4.5]decan-8-yl)ethanone Chemical compound CC=1C(C(=O)CN2CCC3(OCCC3)CC2)=NN(C=2C(=CC=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 KIJMGJWYLBFNAV-UHFFFAOYSA-N 0.000 claims 1
- KGJHVABFBBJFIG-UHFFFAOYSA-N 1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]-2-(3,3-dimethylpiperidin-1-yl)ethanol Chemical compound CC=1C(C(O)CN2CC(C)(C)CCC2)=NN(C=2C(=CC=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 KGJHVABFBBJFIG-UHFFFAOYSA-N 0.000 claims 1
- FLLKDUQZOAVVFU-UHFFFAOYSA-N 1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]-2-(3,5-dimethylpiperidin-1-yl)ethanol Chemical compound C1C(C)CC(C)CN1CC(O)C1=NN(C=2C(=CC=CC=2)Cl)C(C=2C=CC(Cl)=CC=2)=C1C FLLKDUQZOAVVFU-UHFFFAOYSA-N 0.000 claims 1
- CSIFSTSKGZGCOA-UHFFFAOYSA-N 1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]-2-[4-(1-methylcyclopropanecarbonyl)piperazin-1-yl]ethanone Chemical compound CC=1C(C(=O)CN2CCN(CC2)C(=O)C2(C)CC2)=NN(C=2C(=CC=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 CSIFSTSKGZGCOA-UHFFFAOYSA-N 0.000 claims 1
- MJKOCBMDVCJJOQ-UHFFFAOYSA-N 1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]-2-[4-(1-methylpyrrole-2-carbonyl)piperazin-1-yl]ethanone Chemical compound CC=1C(C(=O)CN2CCN(CC2)C(=O)C=2N(C=CC=2)C)=NN(C=2C(=CC=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 MJKOCBMDVCJJOQ-UHFFFAOYSA-N 0.000 claims 1
- ZIKXMOOJNIZFNL-UHFFFAOYSA-N 1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]-2-morpholin-4-ylethanol Chemical compound CC=1C(C(O)CN2CCOCC2)=NN(C=2C(=CC=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 ZIKXMOOJNIZFNL-UHFFFAOYSA-N 0.000 claims 1
- JBCFDMJWDPFMLH-UHFFFAOYSA-N 1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]-2-morpholin-4-ylethanone Chemical compound CC=1C(C(=O)CN2CCOCC2)=NN(C=2C(=CC=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JBCFDMJWDPFMLH-UHFFFAOYSA-N 0.000 claims 1
- WFUGOPUQRHLVDJ-UHFFFAOYSA-N 1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]-2-piperidin-1-ylethanol Chemical compound CC=1C(C(O)CN2CCCCC2)=NN(C=2C(=CC=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 WFUGOPUQRHLVDJ-UHFFFAOYSA-N 0.000 claims 1
- KEKFWCUOYHQBHF-UHFFFAOYSA-N 1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]-2-piperidin-1-ylethanone Chemical compound CC=1C(C(=O)CN2CCCCC2)=NN(C=2C(=CC=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 KEKFWCUOYHQBHF-UHFFFAOYSA-N 0.000 claims 1
- LMVIYCSQQODEFW-UHFFFAOYSA-N 1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]-2-pyrrolidin-1-ylethanone Chemical compound CC=1C(C(=O)CN2CCCC2)=NN(C=2C(=CC=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 LMVIYCSQQODEFW-UHFFFAOYSA-N 0.000 claims 1
- LBBWUMREEVVZRO-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methylimidazol-4-yl]-2-morpholin-4-ylethanone Chemical compound C=1C=C(Cl)C=CC=1N1C(C)=C(C(=O)CN2CCOCC2)N=C1C1=CC=C(Cl)C=C1Cl LBBWUMREEVVZRO-UHFFFAOYSA-N 0.000 claims 1
- HUKVRWGDXWJBMB-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methylimidazol-4-yl]-2-piperidin-1-ylethanone Chemical compound C=1C=C(Cl)C=CC=1N1C(C)=C(C(=O)CN2CCCCC2)N=C1C1=CC=C(Cl)C=C1Cl HUKVRWGDXWJBMB-UHFFFAOYSA-N 0.000 claims 1
- QIDQDWXTIVTKSA-UHFFFAOYSA-N 1-[2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]-2-hydroxyethyl]-4-(propan-2-ylamino)piperidine-4-carboxamide Chemical compound C1CC(NC(C)C)(C(N)=O)CCN1CC(O)C1=NN(C=2C(=CC=CC=2)Cl)C(C=2C=CC(Cl)=CC=2)=C1C QIDQDWXTIVTKSA-UHFFFAOYSA-N 0.000 claims 1
- RSLSHEPQFIRFMG-UHFFFAOYSA-N 1-[2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]morpholin-4-yl]-2-methylpropan-1-one Chemical compound C1N(C(=O)C(C)C)CCOC1C1=NN(C=2C(=CC=CC=2)Cl)C(C=2C=CC(Cl)=CC=2)=C1C RSLSHEPQFIRFMG-UHFFFAOYSA-N 0.000 claims 1
- IEYCJVQOXJOJMF-UHFFFAOYSA-N 1-[4-[2-[5-(4-chlorophenyl)-1-(2-fluorophenyl)-4-methylpyrazol-3-yl]-2-oxoethyl]piperazin-1-yl]-2,2,2-trifluoroethanone Chemical compound CC=1C(C(=O)CN2CCN(CC2)C(=O)C(F)(F)F)=NN(C=2C(=CC=CC=2)F)C=1C1=CC=C(Cl)C=C1 IEYCJVQOXJOJMF-UHFFFAOYSA-N 0.000 claims 1
- KXERESOFXDHWKC-UHFFFAOYSA-N 1-[5-(4-chlorophenyl)-1-(2-fluorophenyl)-4-methylpyrazol-3-yl]-2-morpholin-4-ylethanone Chemical compound CC=1C(C(=O)CN2CCOCC2)=NN(C=2C(=CC=CC=2)F)C=1C1=CC=C(Cl)C=C1 KXERESOFXDHWKC-UHFFFAOYSA-N 0.000 claims 1
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims 1
- OTRVURCEXHPIES-UHFFFAOYSA-N 2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]-4-(4-methylphenyl)sulfonylmorpholine Chemical compound CC=1C(C2OCCN(C2)S(=O)(=O)C=2C=CC(C)=CC=2)=NN(C=2C(=CC=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 OTRVURCEXHPIES-UHFFFAOYSA-N 0.000 claims 1
- FJFXEOSHGKJKNP-UHFFFAOYSA-N 2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]-4-[[4-(trifluoromethyl)phenyl]methyl]morpholine Chemical compound CC=1C(C2OCCN(CC=3C=CC(=CC=3)C(F)(F)F)C2)=NN(C=2C(=CC=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 FJFXEOSHGKJKNP-UHFFFAOYSA-N 0.000 claims 1
- GXUYMCYBKGQKIC-UHFFFAOYSA-N 2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]-4-cyclohexylmorpholine Chemical compound CC=1C(C2OCCN(C2)C2CCCCC2)=NN(C=2C(=CC=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 GXUYMCYBKGQKIC-UHFFFAOYSA-N 0.000 claims 1
- OYJBJEBOPUMIRM-UHFFFAOYSA-N 2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]-4-propan-2-ylsulfonylmorpholine Chemical compound C1N(S(=O)(=O)C(C)C)CCOC1C1=NN(C=2C(=CC=CC=2)Cl)C(C=2C=CC(Cl)=CC=2)=C1C OYJBJEBOPUMIRM-UHFFFAOYSA-N 0.000 claims 1
- UJXKCJMVVWMQAC-UHFFFAOYSA-N 2-[benzyl(propan-2-yl)amino]-1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]ethanol Chemical compound C=1C=CC=CC=1CN(C(C)C)CC(O)C(C=1C)=NN(C=2C(=CC=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 UJXKCJMVVWMQAC-UHFFFAOYSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- CYAYCOCJAVHQSD-UHFFFAOYSA-N 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxylic acid Chemical compound CC=1C(C(O)=O)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 CYAYCOCJAVHQSD-UHFFFAOYSA-N 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010043903 Tobacco abuse Diseases 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 239000000883 anti-obesity agent Substances 0.000 claims 1
- 229940125710 antiobesity agent Drugs 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- UANAQVHSLHQZFG-UHFFFAOYSA-N n-[1-[2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methylpyrazol-3-yl]-2-oxoethyl]piperidin-4-yl]-2,2,2-trifluoroacetamide Chemical compound CC=1C(C(=O)CN2CCC(CC2)NC(=O)C(F)(F)F)=NN(C=2C(=CC=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 UANAQVHSLHQZFG-UHFFFAOYSA-N 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000003401 opiate antagonist Substances 0.000 claims 1
- -1 oxaazepan-4-yl-ethane Chemical compound 0.000 claims 1
- 239000004031 partial agonist Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000007614 solvation Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43291102P | 2002-12-12 | 2002-12-12 | |
| PCT/IB2003/005835 WO2004052864A1 (en) | 2002-12-12 | 2003-12-03 | Pyrazole and imidazole compounds and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006514942A JP2006514942A (ja) | 2006-05-18 |
| JP2006514942A5 true JP2006514942A5 (enExample) | 2006-12-28 |
Family
ID=32508011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004558286A Withdrawn JP2006514942A (ja) | 2002-12-12 | 2003-12-03 | ピラゾールおよびイミダゾール化合物とそれらの使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7247628B2 (enExample) |
| EP (1) | EP1572662A1 (enExample) |
| JP (1) | JP2006514942A (enExample) |
| AU (1) | AU2003286315A1 (enExample) |
| BR (1) | BR0317096A (enExample) |
| CA (1) | CA2505887A1 (enExample) |
| MX (1) | MXPA05005814A (enExample) |
| WO (1) | WO2004052864A1 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6374762B1 (en) * | 1997-10-27 | 2002-04-23 | Correct Craft, Inc. | Water sport towing apparatus |
| CA2499497A1 (en) | 2002-09-27 | 2004-04-08 | Merck & Co., Inc. | Substituted pyrimidines |
| US7329658B2 (en) * | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| CA2515368A1 (en) * | 2003-02-13 | 2004-08-26 | Luciano Rossetti | Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus |
| EP1603585A2 (en) | 2003-03-14 | 2005-12-14 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74 |
| US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
| US20040214856A1 (en) * | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7141669B2 (en) * | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
| WO2004099157A1 (en) * | 2003-05-07 | 2004-11-18 | Pfizer Products Inc. | Cannabinoid receptor ligands and uses thereof |
| US20040224962A1 (en) * | 2003-05-09 | 2004-11-11 | Pfizer Inc | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
| US7232823B2 (en) * | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| JP4831577B2 (ja) * | 2003-07-30 | 2011-12-07 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ピリダジン誘導体および治療剤としての用途 |
| US20050026983A1 (en) * | 2003-07-30 | 2005-02-03 | Pfizer Inc | Imidazole compounds and uses thereof |
| US20050043327A1 (en) * | 2003-08-21 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of addiction in a mammal |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| US7151097B2 (en) * | 2003-11-07 | 2006-12-19 | Pfizer Inc. | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof |
| US7173044B2 (en) * | 2004-02-19 | 2007-02-06 | Solvay Pharmaceuticals B.V. | Imidazoline derivatives having CB1-antagonistic activity |
| EP1781288A2 (en) | 2004-08-19 | 2007-05-09 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| US7786141B2 (en) * | 2004-08-19 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Dihydrospiroindene modulators of muscarinic receptors |
| WO2006041922A2 (en) * | 2004-10-08 | 2006-04-20 | Dara Biosciences, Inc. | Agents and methods for administration to the central nervous system |
| CN101155587A (zh) * | 2004-11-29 | 2008-04-02 | 弗特克斯药品有限公司 | 毒蕈碱受体调节剂 |
| WO2006060190A2 (en) * | 2004-11-30 | 2006-06-08 | Bayer Pharmaceuticals Corporation | Imidazole derivatives |
| WO2006088875A2 (en) * | 2005-02-14 | 2006-08-24 | Albert Einstein College Of Medicine Of Yeshiva University | Intranasal administration of modulators of hypothalamic atp-sensitive potassium channels |
| JP2008542255A (ja) * | 2005-05-27 | 2008-11-27 | ファイザー・プロダクツ・インク | 肥満症の治療または体重減量の維持のためのカンナビノイド−１受容体アンタゴニストおよびミクロソームトリグリセリド輸送タンパク質阻害物質の併用 |
| GB0512099D0 (en) * | 2005-06-14 | 2005-07-20 | Glaxo Group Ltd | Compounds |
| BRPI0613505A2 (pt) | 2005-06-30 | 2011-01-11 | Prosidion Ltd | agonistas de gpcr |
| FR2888236B1 (fr) * | 2005-07-08 | 2007-09-21 | Sanofi Aventis Sa | Derives de n-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl] sulfonamide, leur preparation et leur application en therapeutique |
| GB0516661D0 (en) * | 2005-08-13 | 2005-09-21 | Astrazeneca Ab | Therapeutic agents |
| TW200745096A (en) * | 2005-08-23 | 2007-12-16 | Organon Nv | Indole derivatives |
| WO2007076070A2 (en) * | 2005-12-22 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| GB0602042D0 (en) * | 2006-02-01 | 2006-03-15 | Glaxo Group Ltd | Compounds |
| EP1986638A2 (en) * | 2006-02-21 | 2008-11-05 | Ampla Pharmaceuticals Inc. | Cb1 antagonists and inverse agonists |
| WO2007100670A1 (en) * | 2006-02-22 | 2007-09-07 | Vertex Pharmaceuticals Incorporated | Spiro condensed piperidnes as modulators of muscarinic receptors |
| KR20080094964A (ko) * | 2006-02-22 | 2008-10-27 | 버텍스 파마슈티칼스 인코포레이티드 | 무스카린성 수용체의 조절제 |
| CN101500565A (zh) * | 2006-06-29 | 2009-08-05 | 弗特克斯药品有限公司 | 毒蕈碱性受体的调节剂 |
| ATE469129T1 (de) * | 2006-07-11 | 2010-06-15 | Sanofi Aventis | N-ä(1,5-diphenyl-1h-pyrazol-3- yl)methylüsulfonamid-derivate antagonisten der cb1 rezeptoren der cannabinoide |
| US7297710B1 (en) | 2006-07-12 | 2007-11-20 | Sanofi-Aventis | Derivatives of N-[(1,5-diphenyl-1H-pyrazol-3-yl)methyl]sulfonamide, their preparation and their application in therapeutics |
| CN101553231A (zh) * | 2006-08-15 | 2009-10-07 | 弗特克斯药品有限公司 | 毒蕈碱受体调节剂 |
| CA2660974A1 (en) | 2006-08-18 | 2008-02-21 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| TWI415845B (zh) * | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物 |
| DE102006049452A1 (de) * | 2006-10-17 | 2008-05-08 | Grünenthal GmbH | Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln |
| CA2673359A1 (en) | 2006-12-18 | 2008-06-26 | 7Tm Pharma A/S | Cb1 receptor modulators |
| GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
| JP2010514828A (ja) | 2007-01-04 | 2010-05-06 | プロシディオン・リミテッド | ピペリジンｇｐｃｒアゴニスト |
| CL2008000017A1 (es) | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
| BRPI0806312A2 (pt) | 2007-01-04 | 2011-09-06 | Prosidion Ltd | agonistas cgpr piperidina |
| CL2008000018A1 (es) | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
| FR2911136B1 (fr) * | 2007-01-05 | 2009-02-20 | Sanofi Aventis Sa | Derives de n-(4-cyano-1h-pyrazol-3-yl)methylamine substitues leur preparation et leur application en therapeutique. |
| GB0702862D0 (en) * | 2007-02-14 | 2007-03-28 | Univ Aberdeen | Therapeutic compounds |
| AU2008307440A1 (en) * | 2007-10-03 | 2009-04-09 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
| GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
| SG157299A1 (en) * | 2008-05-09 | 2009-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
| FR2945533B1 (fr) * | 2009-05-12 | 2011-05-27 | Sanofi Aventis | Derives de cyclopenta°c!pyrrolyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique |
| US20130109721A1 (en) * | 2009-12-08 | 2013-05-02 | Ironwood Pharmaceuticals, Inc. | FAAH Inhibitors |
| AR087701A1 (es) * | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | Derivados de pirazol con actividad inhibidora de sglt1 |
| WO2016101118A1 (en) * | 2014-12-23 | 2016-06-30 | Merck Sharp & Dohme Corp. | Amidoethyl azole orexin receptor antagonists |
| WO2017157735A1 (de) | 2016-03-15 | 2017-09-21 | Bayer Cropscience Aktiengesellschaft | Substituierte sulfonylamide zur bekämpfung tierischer schädlinge |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8613591D0 (en) * | 1986-06-04 | 1986-07-09 | Roussel Lab Ltd | Chemical compounds |
| US5078780A (en) * | 1986-10-22 | 1992-01-07 | Ciba-Geigy Corporation | 1,5-diphenylpyrazole-3-carboxylic acid derivatives for the protection of cultivated plants |
| AU611437B2 (en) | 1987-05-29 | 1991-06-13 | Ortho Pharmaceutical Corporation | Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-n-hydroxypropanamides and method for synthesizing the same |
| PH27357A (en) * | 1989-09-22 | 1993-06-21 | Fujisawa Pharmaceutical Co | Pyrazole derivatives and pharmaceutical compositions comprising the same |
| FR2665898B1 (fr) * | 1990-08-20 | 1994-03-11 | Sanofi | Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| FR2714057B1 (fr) * | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
| US5596106A (en) * | 1994-07-15 | 1997-01-21 | Eli Lilly And Company | Cannabinoid receptor antagonists |
| AU3815495A (en) | 1994-11-08 | 1996-05-31 | Eisai Co. Ltd. | Pyrazole derivatives exhibiting anti-inflammatory and analgesic effects |
| US5470862A (en) * | 1995-02-03 | 1995-11-28 | Ohmeda Pharmaceutical Products Division Inc. | Substituted pyrazolyl compounds and methods employing such compounds |
| FR2741621B1 (fr) * | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
| FR2742148B1 (fr) * | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
| ES2213892T3 (es) * | 1997-01-21 | 2004-09-01 | Smithkline Beecham Corporation | Nuevos moduladores del receptor de canabinoides. |
| FR2758723B1 (fr) * | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
| FR2761266B1 (fr) * | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates |
| FR2783246B1 (fr) | 1998-09-11 | 2000-11-17 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les medicaments les contenant |
| KR100652994B1 (ko) * | 1998-09-11 | 2006-11-30 | 아방티 파르마 소시에테 아노님 | 아제티딘 유도체, 이의 제조방법 및 이를 함유하는 약제 |
| FR2789079B3 (fr) * | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
| FR2799124B1 (fr) | 1999-10-01 | 2004-08-13 | Sanofi Synthelabo | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
| DE60030303T2 (de) | 1999-10-18 | 2007-10-11 | The University Of Connecticut, Farmington | Cannabimimetische indolderivate |
| CA2387892A1 (en) | 1999-10-18 | 2001-04-26 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
| FR2800372B1 (fr) | 1999-11-03 | 2001-12-07 | Sanofi Synthelabo | Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant |
| FR2800375B1 (fr) | 1999-11-03 | 2004-07-23 | Sanofi Synthelabo | Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant |
| WO2001040216A1 (en) * | 1999-12-03 | 2001-06-07 | Pfizer Products Inc. | Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents |
| FR2804604B1 (fr) | 2000-02-09 | 2005-05-27 | Sanofi Synthelabo | Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac |
| EP1254115A2 (en) | 2000-02-11 | 2002-11-06 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
| US6479479B2 (en) * | 2000-03-03 | 2002-11-12 | Aventis Pharma S.A. | Azetidine derivatives, their preparation and pharmaceutical compositions containing them |
| US6566356B2 (en) * | 2000-03-03 | 2003-05-20 | Aventis Pharma S.A. | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation |
| US6355631B1 (en) * | 2000-03-03 | 2002-03-12 | Aventis Pharma S.A. | Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation |
| HUP0204519A3 (en) * | 2000-03-23 | 2003-07-28 | Solvay Pharm Bv | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, pharmaceutical compositions containing them and process for their preparations |
| FR2809621B1 (fr) | 2000-05-12 | 2002-09-06 | Sanofi Synthelabo | Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles comme antidiarrheiques |
| US20020019421A1 (en) * | 2000-07-05 | 2002-02-14 | Roni Biberman | Compositions and therapy for substance addiction |
| US20020091114A1 (en) * | 2000-10-04 | 2002-07-11 | Odile Piot-Grosjean | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity |
| PT1354884E (pt) | 2000-12-28 | 2007-12-24 | Ono Pharmaceutical Co | Composto de ciclopenta (d) pirazolo [1,5-a] piramida como antagonista de receptor de crf |
| SI1373216T1 (en) | 2001-03-22 | 2005-06-30 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| ITMI20011483A1 (it) | 2001-07-11 | 2003-01-11 | Res & Innovation Soc Coop A R | Uso di composti come antagonisti funzionali ai recettori centrali deicannabinoidi |
| AU2002319627A1 (en) | 2001-07-20 | 2003-03-03 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| FR2829028B1 (fr) | 2001-08-29 | 2004-12-17 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de |
| FR2829027A1 (fr) | 2001-08-29 | 2003-03-07 | Aventis Pharma Sa | Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson |
| JP2005507875A (ja) | 2001-08-31 | 2005-03-24 | ユニバーシティ オブ コネチカット | カンナビノイド受容体に作用する新規なピラゾール類似体 |
| TWI231757B (en) | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
| KR100903760B1 (ko) | 2001-09-21 | 2009-06-19 | 솔베이 파마슈티칼스 비. 브이 | Ｃｂ1-길항 작용을 가지는 신규한4,5-디하이드로-1ｈ-피라졸 유도체 |
| HUP0402113A3 (en) | 2001-09-21 | 2012-05-29 | Solvay Pharm Bv | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, preparation and use thereof |
| US6509367B1 (en) * | 2001-09-22 | 2003-01-21 | Virginia Commonwealth University | Pyrazole cannabinoid agonist and antagonists |
| EP1432679A1 (en) | 2001-09-24 | 2004-06-30 | Bayer Pharmaceuticals Corporation | Preparation and use of pyrrole derivatives for treating obesity |
| UY27450A1 (es) | 2001-09-24 | 2003-04-30 | Bayer Corp | Preparación y uso de derivados de imidazol para el tratamiento de la obesidad |
| CA2461142A1 (en) | 2001-09-24 | 2003-04-03 | Bayer Pharmaceuticals Corporation | Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity |
| SE0104330D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| SE0104332D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| US20030139386A1 (en) * | 2001-12-21 | 2003-07-24 | Sophie Cote | Pharmaceutical compositions based on azetidine derivatives |
| AU2003219934A1 (en) | 2002-03-06 | 2003-09-22 | Merck And Co., Inc. | Method of treatment or prevention of obesity |
| JP3813152B2 (ja) | 2002-03-12 | 2006-08-23 | メルク エンド カムパニー インコーポレーテッド | 置換アミド類 |
| AR038966A1 (es) | 2002-03-18 | 2005-02-02 | Solvay Pharm Bv | Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1 |
| JP2005528366A (ja) | 2002-03-26 | 2005-09-22 | メルク エンド カムパニー インコーポレーテッド | カンナビノイド受容体モジュレータとしてのスピロ環式アミド |
| ES2192494B1 (es) | 2002-03-27 | 2005-02-16 | Consejo Superior De Investigaciones Cientificas | Derivados de 1,2,4-triazol con propiedades cannabinoides. |
| WO2003082191A2 (en) | 2002-03-28 | 2003-10-09 | Merck & Co., Inc. | Substituted 2,3-diphenyl pyridines |
| FR2837706A1 (fr) | 2002-03-28 | 2003-10-03 | Sanofi Synthelabo | Utilisation d'un antagoniste des recepteurs aux cannabinoides cb1 pour la preparation de medicaments utiles pour traiter les dysfonctionnements sexuels et/ou ameliorer les performances sexuelles |
| CA2480856A1 (en) | 2002-04-05 | 2003-10-23 | Merck & Co., Inc. | Substituted aryl amides |
| FR2838439B1 (fr) | 2002-04-11 | 2005-05-20 | Sanofi Synthelabo | Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant |
| US7667053B2 (en) | 2002-04-12 | 2010-02-23 | Merck & Co., Inc. | Bicyclic amides |
| US6825209B2 (en) * | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
| WO2003095455A2 (en) | 2002-05-10 | 2003-11-20 | Smithkline Beecham Corporation | Substituted pyrazolopyrimidines |
| CN100366207C (zh) | 2002-08-02 | 2008-02-06 | 华沙整形外科股份有限公司 | 用于照明手术空间的系统和技术 |
| JP2006506366A (ja) * | 2002-10-18 | 2006-02-23 | ファイザー・プロダクツ・インク | カンナビノイド受容体リガンドおよびその使用方法 |
| US7129239B2 (en) * | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
-
2003
- 2003-11-04 US US10/702,149 patent/US7247628B2/en not_active Expired - Fee Related
- 2003-12-03 CA CA002505887A patent/CA2505887A1/en not_active Abandoned
- 2003-12-03 AU AU2003286315A patent/AU2003286315A1/en not_active Abandoned
- 2003-12-03 JP JP2004558286A patent/JP2006514942A/ja not_active Withdrawn
- 2003-12-03 EP EP03777058A patent/EP1572662A1/en not_active Withdrawn
- 2003-12-03 BR BR0317096-9A patent/BR0317096A/pt not_active IP Right Cessation
- 2003-12-03 WO PCT/IB2003/005835 patent/WO2004052864A1/en not_active Ceased
- 2003-12-03 MX MXPA05005814A patent/MXPA05005814A/es not_active Application Discontinuation
-
2007
- 2007-06-21 US US11/766,442 patent/US20070254935A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006514942A5 (enExample) | ||
| RU2205827C2 (ru) | Производное ацилпиперазинилпиримидина, способы его получения, фармацевтическая композиция | |
| RU2006144811A (ru) | Новые цис-имидазолины | |
| JP2006500348A5 (enExample) | ||
| RU2439068C2 (ru) | Модуляторы mglur5 | |
| JP2006524225A5 (enExample) | ||
| JP2006513261A5 (enExample) | ||
| JP2005526723A5 (enExample) | ||
| ZA200205551B (en) | Pyrrolidine derivatives as cyclic amp-specific phosphodiesterase inhibitors. | |
| KR940013507A (ko) | 아릴 치환 헤테로사이클릭 화합물 | |
| JP2004521087A5 (enExample) | ||
| JP2013517283A5 (enExample) | ||
| RU2012156925A (ru) | Соединения пиразола в качестве ингибиторов сигма рецепторов | |
| JP2014511869A5 (enExample) | ||
| RU2005134006A (ru) | Производные 4-(4-{гетероциклилалкокси}фенил0-1-(гетероциклилкарбонил)пиперидина и родственные соединения как антагонисты гистамина н3 для лечения неврологических заболеваний, таких как болезнь альцгеймера | |
| JP2007513957A5 (enExample) | ||
| KR20120110123A (ko) | 치환된 벤즈아마이드 유도체 | |
| RU2006124518A (ru) | Ингибиторы фосфодиэстеразы 4, включая аналоги n-замещенного диариламина | |
| JP2019537603A5 (enExample) | ||
| JP2001510831A5 (enExample) | ||
| JP2011512412A5 (enExample) | ||
| RU2005124359A (ru) | Пирролилтиазолы и их применение в качестве обратных агонистов рецептора св 1 | |
| CA2738609C (en) | Piperidine compounds, pharmaceutical composition comprising the same and its use | |
| CA2602781A1 (en) | 1h-pyrazole 4-carboxylamides, their preparation and their use as 11beta-hydroxysteroid dehydrogenase | |
| JP2006525299A5 (enExample) |